Experiment 1324254
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Crocus sativus (IRIDACEAE) |
| Citation | SHAKIBA,M: MOAZEN-ZADEH,E: NOORBALA,AA: JAFARINIA,M: DIVSALAR,P: KASHANI,L: SHAHMANSOURI,N: TAFAKHORI,A: BAYAT,H: AKHONDZADEH.S:. (2018). SAFFRON (CROCUS SATIVUS) VERSUS DULOXETINE FOR TREATMENT OF PATIENTS WITH FIBROMYALGIA: A RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL. 8(6) |
| Amount utilized | |
| Compound isolated | |
| Disease | DOUBLE-BLIND PARALLEL-GROUP CLINICAL TRIAL, OUTPATIENTS WITH FIBROMYALGIA WERE RANDOMIZED TO RECEIVE EITHER SAFFRON 15 MG OR DULOXETINE 30 MG. STARTING WITH 1 CAPSULE PER DAY IN THE FIRST WEEK FOLLOWED BY 2 CAPSULES PER DAY FROM WEEK 2 UNTIL THE END OF WEEK 8. PARTICIPANTS WERE MEN AND WOMEN AGED 18-60 YEARS DIAGNOSED WITH FIBROMYALGIA BASED ON THE AMERICAN COLLEGE OF RHEUMATOLOGY 2010 CRITERIA WHO ALSO HAD A PAIN SCORE≥40 BASED ON VISUAL ANALOGUE SCALE. PRIMARY OUTCOMES INCLUDED DIFFERENCES IN MEAN SCORE CHANGES FROM BASELINE TO ENDPOINT BETWEEN THE TREATMENT ARMS FOR HAMILTON RATING SCALE FOR DEPRESSION, FIBROMYALGIA IMPACT QUESTIONNAIRE, AND BRIEF PAIN INVENTORY. RESULTS: SOCIO-DEMOGRAPHIC CHARACTERISTICS AND BASELINE SCORES WERE SIMILARLY DISTRIBUTED BETWEEN THE TWO TREATMENT ARMS (2N=46). NO SIGNIFICANT DIFFERENCE WAS DETECTED FOR ANY OF THE SCALES NEITHER IN TERMS OF SCORE CHANGES FROM BASELINE TO ENDPOINT BETWEEN THE TWO TREATMENT ARMS NOR IN TERMS OF TIME-TREATMENT INTERACTIONS CONCLUSIONS: SAFFRON AND DULOXETINE DEMONSTRATED COMPARABLE EFFICACY IN TREATMENT OF FIBROMYALGIA SYMPTOMS. |
| Dose amount | 30 MG |
| Number | 0 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | ETOH(95%)EXT |